PD-1/PD-L1 pathway: Current research in breast cancer.

Breast disease Pub Date : 2024-01-01 DOI:10.3233/BD-249006

Salman Ardi Syamsu, Muhammad Faruk, Nilam Smaradania, Elridho Sampepajung, Agung Sindu Pranoto, Febie Irsandy, Iin Fadhilah Utami Tammasse

{"title":"PD-1/PD-L1 pathway: Current research in breast cancer.","authors":"Salman Ardi Syamsu, Muhammad Faruk, Nilam Smaradania, Elridho Sampepajung, Agung Sindu Pranoto, Febie Irsandy, Iin Fadhilah Utami Tammasse","doi":"10.3233/BD-249006","DOIUrl":null,"url":null,"abstract":"Introduction: Immunotherapy has shown encouraging outcomes in breast cancer (BC) treatment in recent years. The programmed cell death ligand 1 (PD-L1) transmembrane protein is suggested to function as a co-inhibitory factor in the immune response, where it collaborates with programmed cell death protein 1 (PD-1) to stimulate apoptosis, suppress cytokine release from PD-1 positive cells, and limit the growth of PD-1 positive cells. Furthermore, in many malignancies, PD-L1 reduces the immune system's response to neoplastic cells. These observations suggest that the PD-1/PD-L1 axis plays a vital role in cancer therapy and the regulation of cancer immune escape mechanisms. This review aimed to provide an overview of the functions of PD-1 and PD-L1 in BC cancer therapy.Methods: This research design is a literature review. The style is a traditional review on topics or variables relating to the PD-1/PD-L1 pathway. A literature search was carried out using three online databases.Results: The search using the keywords yielded a total of 248 studies. Each result was filtered again according to the inclusion and exclusion criteria, resulting in a final total of 4 studies to be included in the literature review.Conclusions: The combination of PD-1/PD-L1 is essential for many malignancies. According to the evidence presented, this combination presents both an opportunity and a challenge in cancer treatment. Since many solid cancers, especially BC, express high levels of PD-1/PD-L1, cancer treatment mainly involves targeted therapies.","PeriodicalId":9224,"journal":{"name":"Breast disease","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11091639/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breast disease","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3233/BD-249006","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Immunotherapy has shown encouraging outcomes in breast cancer (BC) treatment in recent years. The programmed cell death ligand 1 (PD-L1) transmembrane protein is suggested to function as a co-inhibitory factor in the immune response, where it collaborates with programmed cell death protein 1 (PD-1) to stimulate apoptosis, suppress cytokine release from PD-1 positive cells, and limit the growth of PD-1 positive cells. Furthermore, in many malignancies, PD-L1 reduces the immune system's response to neoplastic cells. These observations suggest that the PD-1/PD-L1 axis plays a vital role in cancer therapy and the regulation of cancer immune escape mechanisms. This review aimed to provide an overview of the functions of PD-1 and PD-L1 in BC cancer therapy.

Methods: This research design is a literature review. The style is a traditional review on topics or variables relating to the PD-1/PD-L1 pathway. A literature search was carried out using three online databases.

Results: The search using the keywords yielded a total of 248 studies. Each result was filtered again according to the inclusion and exclusion criteria, resulting in a final total of 4 studies to be included in the literature review.

Conclusions: The combination of PD-1/PD-L1 is essential for many malignancies. According to the evidence presented, this combination presents both an opportunity and a challenge in cancer treatment. Since many solid cancers, especially BC, express high levels of PD-1/PD-L1, cancer treatment mainly involves targeted therapies.

查看原文本刊更多论文

PD-1/PD-L1 通路：乳腺癌研究现状

简介近年来，免疫疗法在乳腺癌（BC）治疗中取得了令人鼓舞的成果。程序性细胞死亡配体 1（PD-L1）跨膜蛋白被认为是免疫反应中的共同抑制因子，它与程序性细胞死亡蛋白 1（PD-1）合作刺激细胞凋亡，抑制 PD-1 阳性细胞释放细胞因子，并限制 PD-1 阳性细胞的生长。此外，在许多恶性肿瘤中，PD-L1 会降低免疫系统对肿瘤细胞的反应。这些观察结果表明，PD-1/PD-L1 轴在癌症治疗和癌症免疫逃逸机制调控中发挥着重要作用。本综述旨在概述 PD-1 和 PD-L1 在 BC 癌症治疗中的功能：本研究设计为文献综述。文体为传统综述，涉及与 PD-1/PD-L1 通路相关的主题或变量。使用三个在线数据库进行了文献检索：结果：使用关键词进行检索共获得 248 项研究。根据纳入和排除标准对每项结果再次进行筛选，最终共有 4 项研究被纳入文献综述：结论：PD-1/PD-L1联合疗法对许多恶性肿瘤都至关重要。结论：PD-1/PD-L1 组合对于许多恶性肿瘤来说都是必不可少的，根据所提供的证据，这种组合在癌症治疗中既是机遇也是挑战。由于许多实体瘤（尤其是 BC）表达高水平的 PD-1/PD-L1，因此癌症治疗主要涉及靶向疗法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Breast disease Medicine-Oncology

CiteScore

1.80

自引率

0.00%

发文量

期刊介绍： The recent expansion of work in the field of breast cancer inevitably will hasten discoveries that will have impact on patient outcome. The breadth of this research that spans basic science, clinical medicine, epidemiology, and public policy poses difficulties for investigators. Not only is it necessary to be facile in comprehending ideas from many disciplines, but also important to understand the public implications of these discoveries. Breast Disease publishes review issues devoted to an in-depth analysis of the scientific and public implications of recent research on a specific problem in breast cancer. Thus, the reviews will not only discuss recent discoveries but will also reflect on their impact in breast cancer research or clinical management.